Diacylglycerol Signaling

382 L. Xiao
Table 19.1 Expression and function of PKC isoforms in lung cancer
Expression in lung cancer
PKC isoform specimens/cells References Function References
a £20% NSCLC (high level) Lahn et al. (2004) Proproliferation and tumorigenicity;PMA- Wang et al. (1999);
induced G /M phase arrest and cellular Oliva et al. (2008);
2
senescence;
Mai et al. (2003);
Promoting nicotine-mediated SCLC
Singhal et al. (2006)
survival;
Up-regulation of the activity of
doxorubicin transporters
b 71% NSCLC Lahn et al. (2006)
d ~7% NSCLC tumor cells Chen et al. (2008); PMA-mediated growth inhibition and G Nakagawa et al. (2005);
1
(frequently expressed Ding et al. (2002); phase arrest;
Clark et al. (2003);
in normal and tumor- Clark et al. (2003); Pro- and antiapoptosis in cell-context and/or Hurbin et al. (2005);
associated stroma); Kim et al. (2007)
stimuli-specific manners
Lee et al. (2005);
Ubiquitously expressed in
Persaud et al. (2005);
NSCLC cell lines
Kim et al. (2007)
e >90% NSCLC Bae et al. (2007) Promoting G /S transition and transformed Bae et al. (2007);
1
growth;
Ding et al. (2002);
Antiapoptosis and chemoresistance
Pardo et al. (2006);
Felber et al. (2007)
i ~70% NSCLC (gene
Regala et al. (2005a); Transformed growth and tumorigenicity; Regala et al. (2005a);
amplification in ~70% Fields and Regala Promoting NNK-mediated cell survival; Regala et al. (2005b);
SCC)
(2007)
Promoting migration and invasion
Jin et al. (2005);
Xu and Deng (2006);
Frederick et al. (2008)
z Low or undetectable in Regala et al. (2005a); Tumor suppressor and antiproliferation; Galvez et al. (2009);
NSCLC
Galvez et al. Promoting nicotine-mediated survival; Xin et al. (2007);
(2009)
Promoting EGF-induced chemotataxis Liu et al. (2009)